Exact Mass: 469.1802

Exact Mass Matches: 469.1802

Found 500 metabolites which its exact mass value is equals to given mass value 469.1802, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Nefazodone

1-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-3-ethyl-4-(2-phenoxyethyl)-4,5-dihydro-1H-1,2,4-triazol-5-one

C25H32ClN5O2 (469.2244)

Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia] D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants D049990 - Membrane Transport Modulators Nefazodone is an orally active phenylpiperazine antidepressant. Nefazodone can potently and selectively block postsynaptic 5-HT2A receptors, and moderately inhibit 5-HT and noradrenaline reuptake. Nefazodone can also relieve the adverse effects of stress on the the immune system of mice. Nefazodone has a high affinity for CYP3A4 isoenzyme, which indicates that it has certain risk of agent-agent interaction. Nefazodone. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=83366-66-9 (retrieved 2024-10-16) (CAS RN: 83366-66-9). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

Indol-3-ylacetyl-myo-inositol L-arabinoside

[(2S,3S,5R,6R)-2,3,5,6-tetrahydroxy-4-[(2S,3R,4S,5S)-3,4,5-trihydroxytetrahydropyran-2-yl]oxy-cyclohexyl] 2-(1H-indol-3-yl)acetate

C21H27NO11 (469.1584)

RO4929097

C22H20F5N3O3 (469.1425)

D004791 - Enzyme Inhibitors > D000091062 - Gamma Secretase Inhibitors and Modulators C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

O-Methyl-4-[(2',3',4'-tri-O-acetyl-alpha-L-rhamnosyloxy)benzyl]thiocarbamate

(2S,3S,4R,5R,6S)-4,5-bis(acetyloxy)-6-(4-{[(methoxymethanethioyl)amino]methyl}phenoxy)-2-methyloxan-3-yl acetate

C21H27NO9S (469.1406)

O-Methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnosyloxy)benzyl]thiocarbamate is a fully acetylated thiocarbamate glycoside. It has been isolated from the leaves of Moringa oleifera (horseradish tree). It is found in fats and oils, herbs and spices, and green vegetables. The trans and cis rotamers differ in the orientation of the NH group with respect to sulfur.

20-COOH-leukotriene E4

(6Z,9Z,11E,13E,15R,16S)-15-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}-16-hydroxyicosa-6,9,11,13-tetraenedioic acid

C23H35NO7S (469.2134)

20-COOH-leukotriene E4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 20-COOH-leukotriene E4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078)

Dactolisib

2-Methyl-2-(4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-1H-imidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile

C30H23N5O (469.1903)

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

N-(2-(3-(Piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide

N-{2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl}quinoxaline-2-carboximidic acid

C25H23N7OS (469.1685)

SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.

Bucladesine

[6-[6-(Butanoylamino)purin-9-yl]-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-D][1,3,2]dioxaphosphinin-7-yl] butanoic acid

C18H24N5O8P (469.1362)

2-Methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide

2-methoxy-N-{3-[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-6-yl]prop-2-en-1-yl}acetamide

C27H27N5O3 (469.2114)

Dacomitinib

N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enimidate

C24H25ClFN5O2 (469.1681)

Ethanol and folate

2-[(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}phenyl)formamido]-5-ethoxy-5-oxopentanoic acid

C21H23N7O6 (469.171)

H-Asp-ala-his-lys-OH

6-Amino-2-{[2-({2-[(2-amino-3-carboxy-1-hydroxypropylidene)amino]-1-hydroxypropylidene}amino)-1-hydroxy-3-(1H-imidazol-5-yl)propylidene]amino}hexanoate

C19H31N7O7 (469.2285)

Oxaprozin glucuronide

6-{[3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoyl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C24H23NO9 (469.1373)

RO4929097

N-{9-hydroxy-8-azatricyclo[9.4.0.0,]pentadeca-1(15),2,4,6,8,11,13-heptaen-10-yl}-2,2-dimethyl-N-(2,2,3,3,3-pentafluoropropyl)propanediimidate

C22H20F5N3O3 (469.1425)

D004791 - Enzyme Inhibitors > D000091062 - Gamma Secretase Inhibitors and Modulators

2-[1-[4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]indol-3-yl]acetic acid

C21H27NO11 (469.1584)

ACon1_000074

C24H27N3O7 (469.1849)

Rhizocarpic acid

C28H23NO6 (469.1525)

O-methyl-4-<(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl>thiocarbamate (E)|O-methyl-4-<(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl>thiocarbamate (Z)|O-methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl]thiocarbamate (E)|O-methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl]thiocarbamate (Z)

O-methyl-4-<(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl>thiocarbamate (E)|O-methyl-4-<(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl>thiocarbamate (Z)|O-methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl]thiocarbamate (E)|O-methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl]thiocarbamate (Z)

C21H27NO9S (469.1406)

latrunculol B

C23H35NO7S (469.2134)

A natural product found in Cacospongia mycofijiensis.

C28H23NO6

C28H23NO6 (469.1525)

SCHEMBL15363691

C26H31NO7 (469.21)

fumiquinazoline K

C26H23N5O4 (469.175)

C25H27NO8

C25H27NO8 (469.1737)

[(4aR,7R,7aR)-6-[6-(butanoylamino)purin-9-yl]-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl] butanoate

C18H24N5O8P (469.1362)

C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CE - Phosphodiesterase inhibitors C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor

Ala Lys His Asp

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-3-(1H-imidazol-4-yl)propanamido]butanedioic acid

C19H31N7O7 (469.2285)

SRT 1720

N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide

C25H23N7OS (469.1685)

SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.

CAY10589

2-[[4-[([1,1-biphenyl]-4-ylmethyl)amino]-6-chloro-2-pyrimidinyl]thio]-octanoic acid

C25H28ClN3O2S (469.1591)

Asn Ala His Glu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]propanamido]-3-(1H-imidazol-4-yl)propanamido]pentanedioic acid

C18H27N7O8 (469.1921)

Gln Trp His

C22H27N7O5 (469.2074)

Gln Ala His Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]propanamido]-3-(1H-imidazol-4-yl)propanamido]butanedioic acid

C18H27N7O8 (469.1921)

(indol-3-yl)acetyl-myo-inositol L-arabinoside

C21H27NO11 (469.1584)

C21H27NO11

NCGC00380387-01_C21H27NO11_

C21H27NO11 (469.1584)

C24H27N3O7_Prolinamide, N-(4-hydroxybenzoyl)valyl-N-(2-carboxy-6-hydroxyphenyl)

NCGC00168819-02_C24H27N3O7_Prolinamide, N-(4-hydroxybenzoyl)valyl-N-(2-carboxy-6-hydroxyphenyl)-

C24H27N3O7 (469.1849)

nefazodone

C25H32ClN5O2 (469.2244)

D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants D049990 - Membrane Transport Modulators Nefazodone is an orally active phenylpiperazine antidepressant. Nefazodone can potently and selectively block postsynaptic 5-HT2A receptors, and moderately inhibit 5-HT and noradrenaline reuptake. Nefazodone can also relieve the adverse effects of stress on the the immune system of mice. Nefazodone has a high affinity for CYP3A4 isoenzyme, which indicates that it has certain risk of agent-agent interaction[1][2][3].

2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(1H-indol-3-yl)propanamido]acetic acid

C22H27N7O5 (469.2074)

Hydroxymaprotiline glucuronide

C26H31NO7 (469.21)

Ala Lys Asp His

(3S)-3-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-3-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C19H31N7O7 (469.2285)

3-Hydroxymaprotiline glucuronide

C26H31NO7 (469.21)

2-[(2R)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(4-hydroxyphenyl)propanamido]-3-sulfanylpropanamido]acetic acid

C20H31N5O6S (469.1995)

Lys Tyr Gly Cys

(2R)-2-{2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(4-hydroxyphenyl)propanamido]acetamido}-3-sulfanylpropanoic acid

C20H31N5O6S (469.1995)

His Trp Gln

C22H27N7O5 (469.2074)

C24H27N3O7 (469.1849)

20-COOH-leukotriene E4

(6Z,9Z,11E,13E,15R,16S)-15-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}-16-hydroxyicosa-6,9,11,13-tetraenedioic acid

C23H35NO7S (469.2134)

20-carboxy-LTE4

6R-(S-cysteinyl)-(5S)-hydroxy-(7E,9E,11Z,14Z)-eicosatetraenedioic acid

C23H35NO7S (469.2134)

Boc-Phe-Phe-Gly-OH

C25H31N3O6 (469.2213)

Erbulozole

C24H27N3O5S (469.1671)

Belotecan hydrochloride

Belotecan hydrochloride(CKD-602)

C25H28ClN3O4 (469.1768)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059004 - Topoisomerase I Inhibitors C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor D004791 - Enzyme Inhibitors

1-[2-[[4-[(2-chloro-4-nitrophenyl)azo]phenyl]ethylamino]ethyl]pyridinium acetate

C23H24ClN5O4 (469.1517)

Dacomitinib

Dacomitinib (PF299804, PF299)

C24H25ClFN5O2 (469.1681)

L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

fmoc-(s)-3-amino-4-(2-trifluoromethyl-phenyl)-butyric acid

C26H22F3NO4 (469.1501)

BENZENE, 1,1-[(4-NITROPHENYL)METHYLENE]BIS[2,4,6-TRIMETHOXY]-

C25H27NO8 (469.1737)

10-formylfolic acid (25 mg)

C20H19N7O7 (469.1346)

CP-724714

2-Methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propen-1-yl]acetamide

C27H27N5O3 (469.2114)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163760 - HER2-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159156 - HER2 Inhibitor

2-Nitrophenyl2,3-di-O-acetyl-4-O-triethylsilyl-b-D-xylopyranoside

C21H31NO9Si (469.1768)

Fmoc-(S)-3-Amino-4-(4-trifluoromethylphenyl)-butyric acid

C26H22F3NO4 (469.1501)

dimenhydrinate

C24H28ClN5O3 (469.1881)

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant

Gandotinib

C23H25ClFN7O (469.1793)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

5-TBDMS-Bz-dA

C23H31N5O4Si (469.2145)

5'-O-TBDMS-Bz-dA is a nucleoside with protective and modification effects.

FMOC aminotriacid

C25H27NO8 (469.1737)

Fmoc-(R)-3-Amino-4-(3-trifluoromethylphenyl)-butyric acid

C26H22F3NO4 (469.1501)

D-Glucopyranose, 2-azido-2-deoxy-3,4-bis-O-(phenylMethyl)-, 1,6-diacetate

C24H27N3O7 (469.1849)

4-[(4-Chlorophenyl)-2-pyridylmethoxy]piperidine p-nitrobenzoic acid salt

C24H24ClN3O5 (469.1404)

(E)-N-(4-(3-(tert-Butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide

C24H27N3O5S (469.1671)

4H-1,2,4-Triazole, 3-(4-(3-(ethylsulfonyl)propyl)bicyclo(2.2.2)oct-1-yl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-

C23H30F3N3O2S (469.2011)

Mycophenolate mofetil hydrochloride

C23H32ClNO7 (469.1867)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D000995 - Antitubercular Agents C471 - Enzyme Inhibitor > C2087 - Inosine Monophosphate Dehydrogenase Inhibitor C308 - Immunotherapeutic Agent > C574 - Immunosuppressant D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors

Sofpironium bromide

C22H32BrNO5 (469.1464)

C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent Sofpironium bromide (BBI 4000) is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH). Sofpironium bromide reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. Sofpironium bromide also has a high afnity for the M1, M2, M4 and M5 subtypes[1].

Tryptamine guanosine carbamate

C21H23N7O6 (469.171)

CID 54733074

L-Phenylalanine, N-((3-hydroxy-5-oxo-4-phenyl-2(5H)-furanylidene)phenylacetyl)-, methyl ester

C28H23NO6 (469.1525)

Awl-II-38.3

C23H18F3N5O3 (469.1362)

3-fluoro-N-[4-[[4-(4-methoxyphenyl)-1-piperazinyl]-oxomethyl]phenyl]benzenesulfonamide

C24H24FN3O4S (469.1471)

3-(4-{2-[2-(2-Bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid

C19H27N5O5S2 (469.1454)

(4as,4br,10bs,12as)-12a-Methyl-1,3-Dioxo-2-(Pyridin-3-Ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-Dodecahydronaphtho[2,1-F]isoquinolin-8-Yl Sulfamate

C24H27N3O5S (469.1671)

(2S)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-1,4-benzoxazin-3-one

C24H25F2N5O3 (469.1925)

Dactolisib

C30H23N5O (469.1903)

2-[(4-{[([1,1-Biphenyl]-4-yl)methyl]amino}-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid

C25H28ClN3O2S (469.1591)

(6Z,9Z,11E,13E,15R,16S)-15-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-16-hydroxyicosa-6,9,11,13-tetraenedioic acid

C23H35NO7S (469.2134)

10-Formyldihydrofolate(2-)

C20H19N7O7-2 (469.1346)

(2R,3R,4S,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(1-hydroxyethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol

C18H35N3O11 (469.2271)

(2S)-2-[[[4-[(2-amino-4-oxo-3H-quinazolin-6-yl)methyl-formylamino]phenyl]-hydroxymethyl]amino]pentanedioic acid

C22H23N5O7 (469.1597)

Ethanol and folate

C21H23N7O6 (469.171)

6-[3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoyloxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C24H23NO9 (469.1373)

2-(4-Nitrophenoxy)-1-[4-(4-phenylphthalazin-1-yl)piperazin-1-yl]ethanone

C26H23N5O4 (469.175)

(indol-3-ylacetyl)-myo-inositol 3-L-arabinoside

C21H27NO11 (469.1584)

[5-(4-Fluorophenyl)-7-(trifluoromethyl)-2-pyrazolo[1,5-a]pyrimidinyl]-[2-(3-pyridinyl)-1-piperidinyl]methanone

C24H19F4N5O (469.1526)

Vertirosan (TN)

C24H28ClN5O3 (469.1881)

1-(1-tert-butyl-5-tetrazolyl)-N-(2-furanylmethyl)-N-(phenylmethyl)-1-[4-(trifluoromethyl)phenyl]methanamine

C25H26F3N5O (469.2089)

3-methyl-2-[(4-methylphenyl)sulfonylamino]pentanoic acid (4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-7-yl) ester

C25H27NO6S (469.1559)

(4-oxo-2,3-dihydro-1H-cyclopenta[c]chromen-7-yl) 4-methyl-2-[(4-methylphenyl)sulfonylamino]pentanoate

C25H27NO6S (469.1559)

4-[3-oxo-1-(3,4,5-trimethoxyanilino)-1H-isoindol-2-yl]-1-piperidinecarboxylic acid ethyl ester

C25H31N3O6 (469.2213)

3-{[4-(4-methoxyphenyl)piperazin-1-yl]carbonyl}benzimidazo[1,2-c]quinazoline-6(5H)-thione

C26H23N5O2S (469.1572)

3-[(3-Acetyloxy-2-undecanoyloxypropoxy)-hydroxyphosphoryl]oxy-2-aminopropanoic acid

C19H36NO10P (469.2077)

[(2S,3S,5R,6R)-2,3,5,6-tetrahydroxy-4-[(2S,3R,4S,5S)-3,4,5-trihydroxytetrahydropyran-2-yl]oxy-cyclohexyl] 2-(1H-indol-3-yl)acetate

C21H27NO11 (469.1584)

methysergide

Methysergide Maleate

C21H27N3O2.C4H4O4 (469.2213)

(4-Methoxybenzyl)thiocarbamic acid 4-O-(tri-O-acetyl-alpha-L-rhamnopyranoside)

C21H27NO9S (469.1406)

20-carboxyleukotriene E4

C23H35NO7S (469.2134)

A leukotriene that is leukotriene E4 in which the terminal methyl grop has been oxidised to the corresponding carboxylic acid.

N(1),N(8)-bis(caffeoyl)spermidine

C25H31N3O6 (469.2213)

A secondary amino compound that is spermidine in which each of the primary amino groups has been mono-acylated by formal condensation with trans-caffeic acid.

2-deoxycytidine-thymidine dimer

C19H27N5O9 (469.1809)

A nucleoside analogue obtained by formal cyclodimerisation of 2-deoxycytidine and thymidine.

LPS 11:3;O3

C17H28NO12P (469.1349)

LPS 12:2;O2

C18H32NO11P (469.1713)

PS 11:0/2:0

C19H36NO10P (469.2077)

PS 13:0

C19H36NO10P (469.2077)

ST 19:5;O6;Tau

C21H27NO9S (469.1406)

ST 20:4;O5;Tau

C22H31NO8S (469.177)

ST 21:3;O4;Tau

C23H35NO7S (469.2134)

(2s)-2-{[(3r)-3-amino-6-{[(1s)-1-carboxy-2-phenylethyl]-c-hydroxycarbonimidoyl}-1-hydroxyhexylidene]amino}-3-phenylpropanoic acid

C25H31N3O6 (469.2213)

(1s,2r,3s,4r,4ar,8as)-2,3-dihydroxy-3,4,8,8a-tetramethyl-4-[(2s)-6-oxo-2h,3h,4h-furo[2,3-c]furan-2-yl]-2,4a,5,6-tetrahydro-1h-naphthalen-1-yl pyridine-3-carboxylate

C26H31NO7 (469.21)

2-({3-amino-6-[(1-carboxy-2-phenylethyl)-c-hydroxycarbonimidoyl]-1-hydroxyhexylidene}amino)-3-phenylpropanoic acid

C25H31N3O6 (469.2213)

(3s,4r,5s)-3,4-dihydroxy-5-[(1s)-2-hydroxy-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl]-3-(1h-indol-3-ylmethyl)oxolan-2-one

C21H27NO11 (469.1584)

10-Formylfolic acid

(2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methyl-formylamino]benzoyl]amino]pentanedioic acid

C20H19N7O7 (469.1346)

4,5-bis(acetyloxy)-6-[4-({[methoxy(sulfanyl)methylidene]amino}methyl)phenoxy]-2-methyloxan-3-yl acetate

C21H27NO9S (469.1406)

4-[({10-amino-10-benzyl-7,9,10a-trihydroxy-3-oxo-1h,2h,5h-pyrrolo[1,2-b]isoquinolin-5-yl}(hydroxy)methylidene)amino]butanoic acid

C24H27N3O7 (469.1849)

2-[3-hexanoyl-9a-methyl-2,9-dioxo-6-(prop-1-en-1-yl)furo[3,2-g]isoquinolin-7-yl]butanedioic acid

C25H27NO8 (469.1737)

(1'r,2r,9r,9as,12'r)-15'-hydroxy-12'-methyl-2-(2-methylpropyl)-2,9a-dihydro-1h-2',10',16'-triazaspiro[imidazo[1,2-a]indole-9,13'-tetracyclo[10.2.2.0²,¹¹.0⁴,⁹]hexadecane]-4',6',8',10',15'-pentaene-3,3'-dione

(1'r,2r,9r,9as,12'r)-15'-hydroxy-12'-methyl-2-(2-methylpropyl)-2,9a-dihydro-1h-2',10',16'-triazaspiro[imidazo[1,2-a]indole-9,13'-tetracyclo[10.2.2.0²,¹¹.0⁴,⁹]hexadecane]-4',6',8',10',15'-pentaene-3,3'-dione

C27H27N5O3 (469.2114)

(3s)-3-{[(2s,5s,6r)-5-amino-6-methyloxan-2-yl]oxy}-4-(1,5-dihydroxy-9,10-dioxoanthracen-2-yl)-3-methylbutanoic acid

C25H27NO8 (469.1737)

3,4-dihydroxy-5-(2-hydroxy-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl)-3-(1h-indol-3-ylmethyl)oxolan-2-one

C21H27NO11 (469.1584)

(1'r,3'r,15'r,28's)-3'-hydroxy-27'-methyl-10',13',17',25',27'-pentaazaspiro[cyclopropane-1,12'-heptacyclo[13.10.2.1³,¹⁰.0⁴,⁹.0¹⁶,²⁵.0¹⁸,²³.0¹³,²⁸]octacosane]-4',6',8',16',18',20',22'-heptaene-11',24',26'-trione

(1'r,3'r,15'r,28's)-3'-hydroxy-27'-methyl-10',13',17',25',27'-pentaazaspiro[cyclopropane-1,12'-heptacyclo[13.10.2.1³,¹⁰.0⁴,⁹.0¹⁶,²⁵.0¹⁸,²³.0¹³,²⁸]octacosane]-4',6',8',16',18',20',22'-heptaene-11',24',26'-trione

C26H23N5O4 (469.175)

4-(5,7-dihydroxy-2-methyl-4-oxochromen-8-yl)-1-methylpiperidin-3-yl 3,4-dimethoxybenzoate

C25H27NO8 (469.1737)

2,3-dihydroxy-3,4,8,8a-tetramethyl-4-{6-oxo-2h,3h,4h-furo[2,3-c]furan-2-yl}-2,4a,5,6-tetrahydro-1h-naphthalen-1-yl pyridine-3-carboxylate

C26H31NO7 (469.21)

3'-hydroxy-27'-methyl-10',13',17',25',27'-pentaazaspiro[cyclopropane-1,12'-heptacyclo[13.10.2.1³,¹⁰.0⁴,⁹.0¹⁶,²⁵.0¹⁸,²³.0¹³,²⁸]octacosane]-4',6',8',16',18',20',22'-heptaene-11',24',26'-trione

3'-hydroxy-27'-methyl-10',13',17',25',27'-pentaazaspiro[cyclopropane-1,12'-heptacyclo[13.10.2.1³,¹⁰.0⁴,⁹.0¹⁶,²⁵.0¹⁸,²³.0¹³,²⁸]octacosane]-4',6',8',16',18',20',22'-heptaene-11',24',26'-trione

C26H23N5O4 (469.175)

(2s,3s,4r,5r,6s)-4,5-bis(acetyloxy)-6-[4-({[methoxy(sulfanyl)methylidene]amino}methyl)phenoxy]-2-methyloxan-3-yl acetate

C21H27NO9S (469.1406)

(2s)-2-[(3-amino-6-{[(1s)-1-carboxy-2-phenylethyl]-c-hydroxycarbonimidoyl}-1-hydroxyhexylidene)amino]-3-phenylpropanoic acid

C25H31N3O6 (469.2213)

(2s,3s,4r,5s,6r)-5-methoxy-6-methyl-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8(13),9,11,14(28),15(19),17,20(27),21(26),22,24-decaene-3,4,18-triol

(2s,3s,4r,5s,6r)-5-methoxy-6-methyl-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-8(13),9,11,14(28),15(19),17,20(27),21(26),22,24-decaene-3,4,18-triol

C27H23N3O5 (469.1638)

15'-hydroxy-12'-methyl-2-(2-methylpropyl)-2,9a-dihydro-1h-2',10',16'-triazaspiro[imidazo[1,2-a]indole-9,13'-tetracyclo[10.2.2.0²,¹¹.0⁴,⁹]hexadecane]-4',6',8',10',15'-pentaene-3,3'-dione

C27H27N5O3 (469.2114)

8,17-dihydroxy-17-(2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl)-9-methoxy-5,12-dimethyl-2,16-dioxabicyclo[13.3.1]nonadeca-4,10-dien-3-one

C23H35NO7S (469.2134)

ethyl 4-oxo-4-[(9s)-4,5,15,16-tetramethoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaen-10-yl]butanoate

C26H31NO7 (469.21)

(1r,4z,8s,9s,10z,12s,15r,17r)-8,17-dihydroxy-17-[(4r)-2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl]-9-methoxy-5,12-dimethyl-2,16-dioxabicyclo[13.3.1]nonadeca-4,10-dien-3-one

C23H35NO7S (469.2134)